ATE542820T1 - Pteridinderivate als inhibitoren der polo-like- kinase zur behandlung von krebs - Google Patents
Pteridinderivate als inhibitoren der polo-like- kinase zur behandlung von krebsInfo
- Publication number
- ATE542820T1 ATE542820T1 AT07824247T AT07824247T ATE542820T1 AT E542820 T1 ATE542820 T1 AT E542820T1 AT 07824247 T AT07824247 T AT 07824247T AT 07824247 T AT07824247 T AT 07824247T AT E542820 T1 ATE542820 T1 AT E542820T1
- Authority
- AT
- Austria
- Prior art keywords
- optionally substituted
- ring
- polo
- treatment
- alkyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000002770 polo like kinase inhibitor Substances 0.000 title 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical class N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 abstract 2
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0621205A GB0621205D0 (en) | 2006-10-25 | 2006-10-25 | Inhibitors of PLK |
| GB0715614A GB0715614D0 (en) | 2007-08-10 | 2007-08-10 | Inhibitors of plk |
| PCT/GB2007/003998 WO2008050096A1 (en) | 2006-10-25 | 2007-10-19 | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE542820T1 true ATE542820T1 (de) | 2012-02-15 |
Family
ID=38896021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07824247T ATE542820T1 (de) | 2006-10-25 | 2007-10-19 | Pteridinderivate als inhibitoren der polo-like- kinase zur behandlung von krebs |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100216802A1 (enExample) |
| EP (1) | EP2079743B1 (enExample) |
| JP (1) | JP2010507639A (enExample) |
| KR (1) | KR20090071668A (enExample) |
| AT (1) | ATE542820T1 (enExample) |
| AU (1) | AU2007310604B2 (enExample) |
| BR (1) | BRPI0718120A2 (enExample) |
| CA (1) | CA2665736A1 (enExample) |
| EA (1) | EA200900593A1 (enExample) |
| IL (1) | IL198082A0 (enExample) |
| MX (1) | MX2009004244A (enExample) |
| NZ (1) | NZ577153A (enExample) |
| WO (1) | WO2008050096A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| CA2668070A1 (en) * | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
| US8129387B2 (en) | 2006-12-14 | 2012-03-06 | Vertex Pharmaceuticals Incorporated | Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors |
| GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| GB0807451D0 (en) * | 2008-04-24 | 2008-05-28 | Chroma Therapeutics Ltd | Inhibitors of PLK |
| EP2318412B1 (en) * | 2008-06-23 | 2013-08-14 | Vertex Pharmceuticals Incorporated | Protein kinase inhibitors |
| CA2728729C (en) | 2008-06-23 | 2016-09-27 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| KR20120081119A (ko) * | 2009-09-04 | 2012-07-18 | 잘리커스 파마슈티컬즈 리미티드 | 통증 및 간질 치료를 위한 치환된 헤테로고리 유도체 |
| CN102020643A (zh) * | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| SI3222616T1 (sl) | 2012-10-17 | 2019-10-30 | Macrophage Pharma Ltd | N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester |
| WO2014134306A1 (en) | 2013-03-01 | 2014-09-04 | Zalicus Pharmaceuticals, Ltd. | Heterocyclic inhibitors of the sodium channel |
| WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| EP3099693A4 (en) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| KR20160111520A (ko) * | 2014-01-31 | 2016-09-26 | 다나-파버 캔서 인스티튜트 인크. | 디히드로프테리디논 유도체 및 그의 용도 |
| US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
| WO2020033823A1 (en) * | 2018-08-10 | 2020-02-13 | Yale University | Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same |
| CN111039944B (zh) * | 2018-10-12 | 2021-11-23 | 中国科学院合肥物质科学研究院 | Mst1激酶抑制剂及其用途 |
| KR102260995B1 (ko) * | 2018-11-28 | 2021-06-04 | 국립암센터 | Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| CN115947728B (zh) * | 2021-10-09 | 2024-01-09 | 沈阳药科大学 | 含磺酰基的二氢喋啶酮衍生物及其应用 |
| EP4479042A1 (en) | 2022-02-18 | 2024-12-25 | Massachusetts Institute Of Technology | Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization |
| CN118047779B (zh) * | 2022-11-09 | 2025-02-11 | 沈阳药科大学 | 含苯联杂芳基的二氢喋啶酮衍生物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| CA2575804A1 (en) * | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinones used as plk (polo like kinase) inhibitors |
| WO2006021548A1 (de) * | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
-
2007
- 2007-10-19 BR BRPI0718120-5A patent/BRPI0718120A2/pt not_active IP Right Cessation
- 2007-10-19 EA EA200900593A patent/EA200900593A1/ru unknown
- 2007-10-19 JP JP2009533934A patent/JP2010507639A/ja not_active Withdrawn
- 2007-10-19 AU AU2007310604A patent/AU2007310604B2/en not_active Ceased
- 2007-10-19 EP EP07824247A patent/EP2079743B1/en not_active Not-in-force
- 2007-10-19 WO PCT/GB2007/003998 patent/WO2008050096A1/en not_active Ceased
- 2007-10-19 KR KR1020097010620A patent/KR20090071668A/ko not_active Withdrawn
- 2007-10-19 MX MX2009004244A patent/MX2009004244A/es not_active Application Discontinuation
- 2007-10-19 NZ NZ577153A patent/NZ577153A/en not_active IP Right Cessation
- 2007-10-19 CA CA002665736A patent/CA2665736A1/en not_active Abandoned
- 2007-10-19 US US12/446,008 patent/US20100216802A1/en not_active Abandoned
- 2007-10-19 AT AT07824247T patent/ATE542820T1/de active
-
2009
- 2009-04-07 IL IL198082A patent/IL198082A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ577153A (en) | 2012-02-24 |
| AU2007310604A1 (en) | 2008-05-02 |
| CA2665736A1 (en) | 2008-05-02 |
| IL198082A0 (en) | 2009-12-24 |
| EP2079743A1 (en) | 2009-07-22 |
| BRPI0718120A2 (pt) | 2013-11-12 |
| JP2010507639A (ja) | 2010-03-11 |
| MX2009004244A (es) | 2009-05-14 |
| US20100216802A1 (en) | 2010-08-26 |
| AU2007310604B2 (en) | 2012-02-02 |
| WO2008050096A1 (en) | 2008-05-02 |
| KR20090071668A (ko) | 2009-07-01 |
| EA200900593A1 (ru) | 2010-06-30 |
| EP2079743B1 (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200900593A1 (ru) | Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| MX2012002059A (es) | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. | |
| BR0316146A (pt) | Derivados de amida do ácido 3-(2-hidróxifenil)-1h-pirazol-4-carboxìlico como inibidores de hsp90 para o tratamento de câncer | |
| PE20120506A1 (es) | Derivados de pirazolopiridina como inhibidores de quinasas | |
| PE20151981A1 (es) | Pontenciador de inhibidores del homologo de zeste | |
| PE20120058A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| TN2010000293A1 (en) | Thiazole derivatives used as pi 3 kinase inhibitors | |
| TW200714589A (en) | Phenylacetamides suitable as protein kinase inhibitors | |
| AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
| MY148566A (en) | Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes | |
| PE20130149A1 (es) | Derivados de la cromenona con actividad anti-tumoral | |
| PE20110213A1 (es) | Derivados de indolinona como inhibidores de quinasa | |
| MX2011009146A (es) | Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh. | |
| MX2010000658A (es) | Derivados de pirimidina 934. | |
| PE20090216A1 (es) | Compuestos triazolil aminopirimidina | |
| DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| IL198267A0 (en) | Ikk-?? serine-threonine protein kinase inhibitors | |
| NZ592429A (en) | PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
| EA202191040A1 (ru) | Производные флаваглина для ингибирования активации онкогена kras | |
| PH12018502411A1 (en) | Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| BR112023014549A2 (pt) | Compostos derivados substituídos com ip4-4,6 | |
| MX2010005787A (es) | Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina. |